<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2268">
 <bold>Methods:</bold> Data of 206 patients with hypercapnic respiratory failure and treated with NIV screened retrospectively. Patients who received asetozolamid during the NIV therapy excluded from the study. We investigated frequency, risk factors for the development of MA and if MA effects PaCO2 reduction rate, NIV, ICU and hospital stay and mortality.
</p>
